pipette
ESEspañol

Biomarker Convert: a novel approach to transform plasma pTau217 results across immunoassay and mass spectrometry analytical platforms

K. J. Quadrini, J. Aubrecht, F. Vernhes, X. Zeng, A. D. Johnson, B. E. Snitz, A. D. Cohen, R. Tooker, M. E. Quiceno, B. M. Campbell, T. K. Karikari, C. J. Swanson

PreprintReal-world use

In the authors' words

INTRODUCTION: We report the development and validation of a novel computational tool to cross-convert plasma pTau217 results from different assays to facilitate recruitment for therapeutic trials and observational studies. METHODS: Participants underwent A{beta} PET imaging and plasma pTau217 measurement on up to three assay platforms across three cohorts. We then developed conversion equations using Deming regression -- collectively named Biomarker Convert -- and evaluated robustness using independent research cohorts. Finally, we modeled the potential impact of pTau217 screening on trial enrollment. RESULTS: While absolute plasma pTau217 concentrations differed, the assays had similar predictive characteristics for A{beta} positivity (LC-MS/MS [C2N], AUC=0.952; Janssen Simoa, AUC=0.946; Lumipulse, AUC=0.929). Biomarker Convert enabled transformation of plasma pTau217 data across assays independent of A{beta} PET and clinical status. Plasma pTau217 reduced A{beta} PET scans in the model screening paradigm by >60%. DISCUSSION: Biomarker Convert equations enable harmonization of plasma pTau217 values from immunoassay and mass spectrometry platforms, supporting direct data comparison.

Main resultThe abstract does not state a limitation.

Appeared: Friday, October 2. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.28.26363900